ClinicalTrials.gg
CompletedNCT00783718GEMINI IUpdated Jul 18, 2014Results posted

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

A Phase 3 interventional study of vedolizumab and Placebo in Ulcerative Colitis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 105 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
895
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
3rd of 38
895 · median 110
Started
2009
with 1 other
Phase 3
14 of 38
3 open now
Registered
2nd of 38
by date
Lead sponsor
3 of 38
Millennium Pharmaceuticals, Inc.

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 14 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.

Read the detailed description

This multicenter, phase 3, randomized, blinded, placebo-controlled study in patients with moderately to severely active ulcerative colitis comprises two phases:

  • The Induction Phase, designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
  • The Maintenance Phase, designed to establish the efficacy and safety of vedolizumab for the maintenance of clinical response and remission.

The 6-week Induction Phase contained 2 cohorts of participants: Cohort 1 participants were randomized and treated with double-blind study drug, and Cohort 2 participants were treated with open-label vedolizumab. The second cohort was enrolled to ensure that the sample size of Induction Phase responders randomized into the Maintenance Study provided sufficient power for the Maintenance Study primary efficacy analysis. These participants did not contribute to the efficacy analyses performed for the Induction Study. Participants in both cohorts were assessed for treatment response at Week 6.

In the Maintenance Phase vedolizumab-treated participants from both Cohort 1 and Cohort 2 who demonstrated a clinical response were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks (Q4W), vedolizumab administered every 8 weeks (Q8W), or placebo. Vedolizumab-treated participants who did not demonstrate response at Week 6 continued treatment with open-label vedolizumab, administered Q4W. Participants treated with double-blind placebo in the Induction Phase continued on double-blind placebo during the Maintenance Phase, regardless of treatment response during induction. The Maintenance Phase began at Week 6 and concluded with Week 52 assessments.

After the Week 52 assessments, participants meeting protocol-defined criteria were eligible to enroll in Study C13008 (NCT00790933; Long-term Safety) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may also have been eligible for Study C13008. Participants who did not enroll into Study C13008 were to complete a final on-study safety assessment at Week 66 (or final safety visit 16 weeks after the last dose) in the Maintenance Phase of Study C13006.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  1. Diagnosis of moderately to severely active ulcerative colitis
  2. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance at least 1 of the following agents:

    1. Immunomodulators
    2. Tumor necrosis factor-alpha (TNFα) antagonists
  3. May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Evidence of abdominal abscess at the initial screening visit
  2. Extensive colonic resection, subtotal or total colectomy
  3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  4. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol
  5. Chronic or C infection
  6. Active or latent tuberculosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
895 participants (actual)

Study arms

  • Experimental
    Vedolizumab

    In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15). In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.

    Drug: vedolizumab

  • Placebo comparator
    Placebo

    In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

    Other: Placebo

Interventions

  • Vedolizumab for intravenous infusion

    Also known as: Entyvio, MLN0002, MLN02, LDP-02

  • OtherPlacebo

    Placebo intravenous infusion

06

What researchers measure

Primary outcomes

  1. Induction Phase: Percentage of Participants With a Clinical Response at Week 6

    Clinical response is defined as a reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical response.

    Time frame: Baseline and Week 6

  2. Maintenance Phase: Percentage of Participants in Clinical Remission at Week 52

    Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 52

Secondary outcomes

  1. Induction Phase: Percentage of Participants in Clinical Remission at Week 6

    Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

    Time frame: Week 6

  2. Induction Phase: Percentage of Participants With Mucosal Healing at Week 6

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.

    Time frame: Week 6

  3. Maintenance Phase: Percentage of Participants With Durable Clinical Response

    Durable clinical response is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical response.

    Time frame: Baseline, Week 6 and Week 52

  4. Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 52

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.

    Time frame: Week 52

  5. Maintenance Phase: Percentage of Participants With Durable Clinical Remission

    Durable clinical remission is defined as complete Mayo score of ≤ 2 points and no individual subscore \> 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission.

    Time frame: Week 6 and Week 52

  6. Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52

    Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free remission.

    Time frame: Week 52

07

Results

Posted Jul 18, 2014

Participant flow

Participants took part in the study at 211 investigative sites worldwide. The Induction Phase contained 2 cohorts. The eligibility criteria for both cohorts were identical. The purpose of Cohort 2 was to provide enough responders to power the Maintenance Phase primary efficacy analysis.

Induction Phase
Participant flow — Induction Phase
MilestonePlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab Q8WMaintenance Phase: Vedolizumab Q4WMaintenance Phase: Non-responders
Started1492255210000
Completed1352184850000
Not completed147360000
Withdrew: Adverse event4070000
Withdrew: Protocol violation1160000
Withdrew: Lack of efficacy52140000
Withdrew: Withdrawal by subject3480000
Withdrew: Lost to follow-up1010000
Maintenance Phase
Participant flow — Maintenance Phase
MilestonePlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab Q8WMaintenance Phase: Vedolizumab Q4WMaintenance Phase: Non-responders
Started13500126122125330
Completed3000487784135
Not completed10500784541195
Withdrew: Adverse event1200157616
Withdrew: Protocol violation1000002
Withdrew: Lack of efficacy8300613133155
Withdrew: Withdrawal by subject60025220
Withdrew: Lost to follow-up3000202

Outcome measures

PrimaryInduction Phase: Percentage of Participants With a Clinical Response at Week 6

Clinical response is defined as a reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical response.

Time frame:
Baseline and Week 6
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants With a Clinical Response at Week 6
percentage of participantsPlaceboDB Vedolizumab
Induction Phase: Percentage of Participants With a Clinical Response at Week 625.5 (18.5 to 32.5)47.1 (40.6 to 53.6)
Statistical analysis
  • Placebo vs DB Vedolizumab · Cochran-Mantel-Haenszel · p = < 0.0001 · Risk difference (rd): 21.7 · 95% CI 11.6 to 31.7
PrimaryMaintenance Phase: Percentage of Participants in Clinical Remission at Week 52

Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants in Clinical Remission at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants in Clinical Remission at Week 5215.9 (9.5 to 22.3)41.8 (33.1 to 50.6)44.8 (36.1 to 53.5)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 26.1 · 95% CI 14.9 to 37.2
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 29.1 · 95% CI 17.9 to 40.4
SecondaryInduction Phase: Percentage of Participants in Clinical Remission at Week 6

Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants in Clinical Remission at Week 6
percentage of participantsPlaceboDB Vedolizumab
Induction Phase: Percentage of Participants in Clinical Remission at Week 65.4 (1.7 to 9.0)16.9 (12.0 to 21.8)
Statistical analysis
  • Placebo vs DB Vedolizumab · Cochran-Mantel-Haenszel · p = 0.0009 (P-value is based on the CMH chi-square test, with stratification according to: 1) concomitant use of oral corticosteroids (yes/no); and 2) previous exposure to TNFα antagonists or concomitant immunomodulator use (yes/no).) · Risk difference (rd): 11.5 · 95% CI 4.7 to 18.3
SecondaryInduction Phase: Percentage of Participants With Mucosal Healing at Week 6

Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants With Mucosal Healing at Week 6
percentage of participantsPlaceboDB Vedolizumab
Induction Phase: Percentage of Participants With Mucosal Healing at Week 624.8 (17.9 to 31.8)40.9 (34.5 to 47.3)
Statistical analysis
  • Placebo vs DB Vedolizumab · Cochran-Mantel-Haenszel · p = 0.0012 (P-value is based on the CMH chi-square test, with stratification according to: 1) concomitant use of oral corticosteroids (yes/no); and 2) previous exposure to TNFα antagonists or concomitant immunomodulator use (yes/no).) · Risk difference (rd): 16.1 · 95% CI 6.4 to 25.9
SecondaryMaintenance Phase: Percentage of Participants With Durable Clinical Response

Durable clinical response is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical response.

Time frame:
Baseline, Week 6 and Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Durable Clinical Response
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Durable Clinical Response23.8 (16.4 to 31.2)56.6 (47.8 to 65.4)52.0 (43.2 to 60.8)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 32.8 · 95% CI 20.8 to 44.7
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 28.5 · 95% CI 16.7 to 40.3
SecondaryMaintenance Phase: Percentage of Participants With Mucosal Healing at Week 52

Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 5219.8 (12.9 to 26.8)51.6 (42.8 to 60.5)56.0 (47.3 to 64.7)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 32.0 · 95% CI 20.3 to 43.8
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 36.3 · 95% CI 24.4 to 48.3
SecondaryMaintenance Phase: Percentage of Participants With Durable Clinical Remission

Durable clinical remission is defined as complete Mayo score of ≤ 2 points and no individual subscore \> 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission.

Time frame:
Week 6 and Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Durable Clinical Remission8.7 (3.8 to 13.7)20.5 (13.3 to 27.7)24.0 (16.5 to 31.5)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.0079 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 11.8 · 95% CI 3.1 to 20.5
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = 0.0009 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 15.3 · 95% CI 6.2 to 24.4
SecondaryMaintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52

Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free remission.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52
percentage of participantsPlaceboVedolizumab Q8WVedolizumab Q4W
Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 5213.9 (5.9 to 21.9)31.4 (20.6 to 42.3)45.2 (33.8 to 56.6)
Statistical analysis
  • Placebo vs Vedolizumab Q8W · Cochran-Mantel-Haenszel · p = 0.0120 (P-value based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 17.6 · 95% CI 3.9 to 31.3
  • Placebo vs Vedolizumab Q4W · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value is based on the CMH chi-square test, with 3 stratification factors: concomitant use of oral corticosteroids; previous exposure to TNFα antagonists or concomitant immunomodulator use; enrollment in Cohort 1 or 2 in the Induction Phase.) · Risk difference (rd): 31.4 · 95% CI 16.6 to 46.2

Adverse events

Collected over From the start of the Induction Phase until a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—17/149 (11.4%)67/149 (45%)
Vedolizumab Then Placebo—20/126 (15.9%)69/126 (54.8%)
Vedolizumab—77/620 (12.4%)321/620 (51.8%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPlaceboVedolizumab Then PlaceboVedolizumab
Colitis ulcerativeGastrointestinal disorders10/1497/12647/620
AppendicitisInfections and infestations0/1492/1260/620
Colon dysplasiaGastrointestinal disorders0/1491/1260/620
Rectal haemorrhageGastrointestinal disorders0/1491/1260/620
InfectionInfections and infestations0/1491/1260/620
PneumoniaInfections and infestations0/1491/1260/620
ConcussionInjury, poisoning and procedural complications0/1491/1260/620
Pubis fractureInjury, poisoning and procedural complications0/1491/1260/620
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1491/1260/620
Aortic valve stenosisCardiac disorders0/1491/1260/620
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboVedolizumab Then PlaceboVedolizumab
Colitis ulcerativeGastrointestinal disorders20/14922/12657/620
NasopharyngitisInfections and infestations11/14915/12680/620
HeadacheNervous system disorders13/14915/12680/620
ArthralgiaMusculoskeletal and connective tissue disorders10/14915/12656/620
Upper respiratory tract infectionInfections and infestations8/14913/12652/620
NauseaGastrointestinal disorders11/1498/12638/620
AnaemiaBlood and lymphatic system disorders10/1494/12635/620
CoughRespiratory, thoracic and mediastinal disorders7/1496/12636/620
BronchitisInfections and infestations5/1497/12623/620
Abdominal painGastrointestinal disorders7/1492/12634/620

Baseline characteristics

Baseline characteristics are provided for the Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0-6), according to the actual study drug received.

Age, Continuous
Age, Continuous(years)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Mean41.2 ± 12.5040.1 ± 13.1140.1 ± 13.2740.3 ± 13.09
Age, Customized
Age, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
< 355386214353
≥ 3596139307542
Age, Customized
Age, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
< 65142217503862
≥ 65781833
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Female5793220370
Male92132301525
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
White115183436734
Black25512
Asian323667135
Other011314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Hispanic or Latino5103146
Not Hispanic or Latino140211481832
Not reported44917
Region of Enrollment
Region of Enrollment(participants)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Australia7172953
Austria431219
Belgium7143556
Bulgaria2136
Canada16146292
Czech Republic7121938
Denmark27514
Estonia14510
France131317
Germany011617
Greece0145
Hong Kong0011
Hungary26816
Iceland0123
India18162458
Ireland0011
Israel0112
Italy191121
Korea, Republic of5102641
Latvia1203
Malaysia5229
Netherlands1023
New Zealand05611
Norway2169
Poland265260
Russian Federation9152549
Singapore0011
South Africa451019
Spain0022
Switzerland2136
Turkey0336
United Kingdom2046
United States4764127238
Body Weight
Body Weight(kg)PlaceboInduction Phase: DB VedolizumabInduction Phase: OL VedolizumabTotal
Mean72.4 ± 17.6572.4 ± 17.1174.2 ± 19.3273.4 ± 18.51

10 further baseline measures are reported on the registry.

08

Study locations

105 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Apex Clinical Trials
    Birmingham, Alabama 35234, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Gastrointestinal Bioscience
    Los Angeles, California 90067, United States
  • Paramount Medical Specialty
    Montebello, California 90640, United States
  • Capital Gastroenterology Consultants Medical Group
    Sacramento, California 95815, United States
  • Clinical Applications Laboratories Inc.
    San Diego, California 92103, United States
  • Desta Digestive Disease Medical Center
    San Diego, California 92114, United States
  • University of Colorado Health Sciences Center
    Aurora, Colorado 80045, United States
  • Gastroenterology of the Rockies
    Lafayette, Colorado 80026, United States
  • Rocky Mountain Gastroenterology Associates P.L.L.C.
    Lakewood, Colorado 80215, United States
  • Arapahoe Gastroenterology Associates P.C
    Littleton, Colorado 80120, United States
  • South Denver Gastroenterology
    Lone Tree, Colorado 80124, United States
  • Lynn Institute of Pueblo
    Pueblo, Colorado 81007, United States
  • Gastroenterology Center of Connecticut, P.C.
    Hamden, Connecticut 06518, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • University of Florida, Jacksonville
    Jacksonville, Florida 32209, United States
  • East Coast Institute for Research
    Jacksonville, Florida 32223, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Osler Clinical Research
    Melbourne, Florida 32901, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • United Medical Research Institute
    New Smyrna Beach, Florida 32168, United States
  • Compass Research LLC
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • West Wind'r Research & Development, LLC
    Tampa, Florida 33607, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Digestive Research Associates
    Newnan, Georgia 30263, United States
  • St. Joseph's/Candler Health System
    Savannah, Georgia 31405, United States
  • DLW Research System
    Snellville, Georgia 30039, United States
  • Carle Clinic Association P.C.
    Urbana, Illinois 61801, United States
  • Digestive & Liver Consultants
    Clive, Iowa 50325, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • University Of Kansas
    Kansas City, Kansas 66160, United States
  • Cotton O'Neil Digestive Health Center
    Topeka, Kansas 66606, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Gastroenterology Associates
    Baton Rouge, Louisiana 70809, United States
  • University of Maryland Medical Group
    Baltimore, Maryland 21201, United States
  • Metropolitan Gastroenterology Group, P.C.
    Chevy Chase, Maryland 20815, United States
  • Shah Associates
    Prince Frederick, Maryland 20678, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • The Center for Clinical Studies
    Dearborn, Michigan 48124, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55486, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Truman Medical Center
    Kansas City, Missouri 64108, United States
  • Center for Digestive and Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • St. Louis Center for Clinical Research
    St. Louis, Missouri 63128, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Affiliates in Gastroenterology PA
    Morristown, New Jersey 07960, United States
  • University of Medicine and Dentistry of New Jersey-NJMS
    New Brunswick, New Jersey 08903, United States
  • The Gastroenterology Group of South Jersey
    Vineland, New Jersey 08360, United States
  • Hepatobiliary Associates of New York
    Bayside, New York 11358, United States
  • Digestive Health Physician
    Cheektowaga, New York 14225, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Long Island Gastroenterology Group, P.C.
    Merrick, New York 11566, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Present Chapman Marion Steinlauf MD PC
    New York, New York 10028, United States
  • Kim, Chung MD (Private Practice)
    Pittsford, New York 14534, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Long Island Digestive Disease Consultants
    Setauket, New York 11733, United States
  • SUNY Stony Brook University Medical Center
    Stonybrook, New York 11794, United States
  • Syracuse Gastroenterological Associates
    Syracuse, New York 13210, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroentology and Hepatology, P.L.L.C
    Charlotte, North Carolina 28207, United States
  • Northwest Piedmont Clinical Research, Inc.
    Elkin, North Carolina 28621, United States
  • Burke Research Associates
    Morganton, North Carolina 28655, United States
  • Consultants for Clinical Research Inc.
    Cincinnati, Ohio 45219, United States
  • Dayton Science Institute
    Dayton, Ohio 45415, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • The Oregon Clinic-West Hills Gastroenterology
    Portland, Oregon 97225, United States
  • University of Pittsburgh Medical Center - Cancer Centers
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University Of SC CAR
    Charleston, South Carolina 29425, United States
  • Gastroenterology Center of the MidSouth, PC
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Austin Gastroenterology, PA
    Austin, Texas 78705, United States
  • Bayou City Research, Ltd.
    Houston, Texas 77024, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Gastroenterology Consultants
    Houston, Texas 77034, United States
  • Jacon Medical Research Associates
    Houston, Texas 77090, United States
  • Digestive Health Center
    Pasadena, Texas 77504, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • Gastroenterology Clinic of San Antonio
    San Antonio, Texas 78229, United States
  • Stone Oak Research Foundation
    San Antonio, Texas 78258, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • Granite Peaks Gastroenterology
    Sandy, Utah 84094, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Gastroenterology Associates of Northern Virginia
    Fairfax, Virginia 22031, United States
  • Digestive and Liver Disease Specialist Ltd
    Norfolk, Virginia 23502, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Puget Sound Medical Research
    Edmonds, Washington 98026, United States
  • Pharmaseek, LLC
    Madison, Wisconsin 53717, United States

Showing the first 100 of 105 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. PubMed 23964932 ↗
  • Dulai PS, Feagan BG, Sands BE, Chen J, Lasch K, Lirio RA. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023 Feb;21(2):456-466.e7. doi: 10.1016/j.cgh.2022.07.027. Epub 2022 Aug 4. PubMed 35934286 ↗
  • Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. AAPS J. 2020 Nov 16;23(1):3. doi: 10.1208/s12248-020-00518-0. PubMed 33200296 ↗
  • Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10. PubMed 32635680 ↗
  • Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol. 2020 Jun 11;13:211-220. doi: 10.2147/CEG.S248597. eCollection 2020. PubMed 32606883 ↗
  • Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2952-2961.e8. doi: 10.1016/j.cgh.2020.02.010. Epub 2020 Feb 13. PubMed 32062041 ↗
  • Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035. doi: 10.1093/ibd/izy323. PubMed 30365009 ↗
  • Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019 Feb 1;13(2):172-181. doi: 10.1093/ecco-jcc/jjy149. PubMed 30285104 ↗
  • Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125. PubMed 30203005 ↗
  • Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29. Erratum In: Clin Gastroenterol Hepatol. 2020 Mar;18(3):759. doi: 10.1016/j.cgh.2020.01.013. PubMed 29857145 ↗
  • Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018 Jan;67(1):43-52. doi: 10.1136/gutjnl-2016-312293. Epub 2016 Oct 7. PubMed 27802155 ↗
  • Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 Feb;15(2):229-239.e5. doi: 10.1016/j.cgh.2016.08.044. Epub 2016 Sep 14. PubMed 27639327 ↗
  • Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. PubMed 26893500 ↗
  • Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum In: Aliment Pharmacol Ther. 2015 Nov;42(9):1135. doi: 10.1111/apt.13365. PubMed 25996351 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 7 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2008
First posted
Nov 2, 2008
Start
Jan 2009
Primary completionActual
Dec 2011
CompletionActual
Mar 2012
Results delay requested
Jan 14, 2013
Results first posted
Jul 18, 2014
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00783718
Responsible party
Sponsor
First posted
Nov 2, 2008
Start date
Jan 2009
Primary completion
Dec 2011
Completion
Mar 2012
Results posted
Jul 18, 2014
Last update
Jul 18, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion